Free Trial

Hypermarcas (OTCMKTS:HYPMY) Sees Large Volume Increase - Should You Buy?

Hypermarcas logo with Medical background

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) shares saw strong trading volume on Wednesday . 361,579 shares changed hands during trading, an increase of 463% from the previous session's volume of 64,203 shares.The stock last traded at $4.86 and had previously closed at $4.79.

Wall Street Analyst Weigh In

Separately, Scotiabank raised Hypermarcas to a "strong-buy" rating in a report on Thursday, July 17th.

Get Our Latest Research Report on Hypermarcas

Hypermarcas Price Performance

The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of 19.38 and a beta of 0.81. The company has a fifty day simple moving average of $4.71 and a 200 day simple moving average of $3.88. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.80 and a current ratio of 1.26.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The company reported ($0.04) earnings per share for the quarter. The business had revenue of $184.34 million during the quarter. Hypermarcas had a return on equity of 6.95% and a net margin of 12.51%.

Hypermarcas Announces Dividend

The firm also recently announced a dividend, which will be paid on Friday, January 8th. Stockholders of record on Tuesday, July 1st will be paid a $0.0345 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a dividend yield of 2.81%. Hypermarcas's payout ratio is presently 58.33%.

Hypermarcas Company Profile

(Get Free Report)

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

Read More

Should You Invest $1,000 in Hypermarcas Right Now?

Before you consider Hypermarcas, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hypermarcas wasn't on the list.

While Hypermarcas currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines